PATENT CLAIM ANALYSIS

Application Number: 15957739
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "487000"]

Abstract:
Compounds according to formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Claim (Index 63):
The method according to  claim 59  or  60  further comprising administering at least one additional anticancer agent or therapy selected from nivolumab, pembrolizumab, atezolizumab, ipilimumab, chemotherapy, radiation therapy, and resection therapy, to a patient in need thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.13793
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15825993', '13451370', '11008713', '11009841', '11010177']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8113970441286366
- 35 USC 102 Novelty (BERT): 0.5344965331798819
- Combined Prediction Score: 0.7837069930337611
- Mean Citation Score: 379.489292
- Max Citation Score: 383.7718
- Similarity Product: 211.09784952294825

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test